Cancer Research The Future of Cancer Research: Science and Patient Impact  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Agathanggelou, A.
Right arrow Articles by Latif, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Agathanggelou, A.
Right arrow Articles by Latif, F.
[Cancer Research 63, 5344-5351, September 1, 2003]
© 2003 American Association for Cancer Research


Regular Articles

Identification of Novel Gene Expression Targets for the Ras Association Domain Family 1 (RASSF1A) Tumor Suppressor Gene in Non-Small Cell Lung Cancer and Neuroblastoma1

Angelo Agathanggelou, Ivan Bièche, Jalal Ahmed-Choudhury, Barbara Nicke, Reinhard Dammann, Shairaz Baksh, Boning Gao, John D. Minna, Julian Downward, Eamonn R. Maher and Farida Latif2

Section of Medical and Molecular Genetics, Division of Reproductive and Child Health, University of Birmingham, Birmingham B15 2TT, United Kingdom [A. A., J. A-C., E. R. M., F. L.]; Laboratoire d’Oncogénétique-INSERM E0017, Centre René Huguenin, F-92210 St-Cloud, France [I. B.]; Signal Transduction Laboratory, R222, Cancer Research United Kingdom London Research Institute, London WC2A 3PX, United Kingdom [B. N., S. B., J. D.]; AG Tumorgenetik der Medizinischen Fakultät, Martin-Luther Universität Halle-Wittenberg, D-06097 Halle (Saale), Germany [R. D.]; Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center at Dallas, Texas 75390-8593 [B. G., J. D. M.]; and Cancer Research United Kingdom Renal Molecular Oncology Research Group, University of Birmingham, Birmingham B15 2TG, United Kingdom [E. R. M., F. L.]

RASSF1A is a recently identified 3p21.3 tumor suppressor gene. The high frequency of epigenetic inactivation of this gene in a wide range of human sporadic cancers including non-small cell lung cancer (NSCLC) and neuroblastoma suggests that RASSF1A inactivation is important for tumor development. Although little is known about the function of RASSF1A, preliminary data suggests that it may have multiple functions. To gain insight into RASSF1A functions in an unbiased manner, we have characterized the expression profile of a lung cancer cell line (A549) transfected with RASSF1A. Initially we demonstrated that transient expression of RASSF1A into the NSCLC cell line A549 induced G1 cell cycle arrest, as measured by propidium iodide staining. Furthermore, annexin-V staining showed that RASSF1A-expressing cells had an increased sensitivity to staurosporine-induced apoptosis. We then screened a cDNA microarray containing more than 6000 probes to identify genes differentially regulated by RASSF1A. Sixty-six genes showed at least a 2-fold change in expression. Among these were many genes with relevance to tumorigenesis involved in transcription, cytoskeleton, signaling, cell cycle, cell adhesion, and apoptosis. For 22 genes we confirmed the microarray results by real-time RT-PCR and/or Northern blotting. In silico, we were able to confirm the majority of these genes in other NSCLC cell lines using published data on gene expression profiles. Furthermore, we confirmed 10 genes at the RNA level in two neuroblastoma cell lines, indicating that these RASSF1A target genes have relevance in non-lung cell backgrounds. Protein analysis of six genes (ETS2, Cyclin D3, CDH2, DAPK1, TXN, and CTSL) showed that the changes induced by RASSF1A at the RNA level correlated with changes in protein expression in both non-small cell lung cancer and neuroblastoma cell lines. Finally, we have used a transient assay to demonstrate the induction of CDH2 and TGM2 by RASSF1A in NSCLC cell lines. We have identified several novel targets for RASSF1A tumor suppressor gene both at the RNA and the protein levels in two different cellular backgrounds. The identified targets are involved in diverse cellular processes; this should help toward understanding mechanisms that contribute to RASSF1A biological activity.




This article has been cited by other articles:


Home page
J. Cell Sci.Home page
H. Donninger, M. D. Vos, and G. J. Clark
The RASSF1A tumor suppressor
J. Cell Sci., September 15, 2007; 120(18): 3163 - 3172.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
Y. G. Amaar, M. G. Minera, L. K. Hatran, D. D. Strong, S. Mohan, and M. E. Reeves
Ras association domain family 1C protein stimulates human lung cancer cell proliferation
Am J Physiol Lung Cell Mol Physiol, December 1, 2006; 291(6): L1185 - L1190.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
I. Ibanez de Caceres, E. Dulaimi, A. M. Hoffman, T. Al-Saleem, R. G. Uzzo, and P. Cairns
Identification of novel target genes by an epigenetic reactivation screen of renal cancer.
Cancer Res., May 15, 2006; 66(10): 5021 - 5028.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Dallol, A. Agathanggelou, S. Tommasi, G. P. Pfeifer, E. R. Maher, and F. Latif
Involvement of the RASSF1A Tumor Suppressor Gene in Controlling Cell Migration
Cancer Res., September 1, 2005; 65(17): 7653 - 7659.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Agathanggelou, W. N. Cooper, and F. Latif
Role of the Ras-Association Domain Family 1 Tumor Suppressor Gene in Human Cancers
Cancer Res., May 1, 2005; 65(9): 3497 - 3508.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Ahmed-Choudhury, A. Agathanggelou, S. L. Fenton, C. Ricketts, G. J. Clark, E. R. Maher, and F. Latif
Transcriptional Regulation of Cyclin A2 by RASSF1A through the Enhanced Binding of p120E4F to the Cyclin A2 Promoter
Cancer Res., April 1, 2005; 65(7): 2690 - 2697.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Dallol, A. Agathanggelou, S. L. Fenton, J. Ahmed-Choudhury, L. Hesson, M. D. Vos, G. J. Clark, J. Downward, E. R. Maher, and F. Latif
RASSF1A Interacts with Microtubule-Associated Proteins and Modulates Microtubule Dynamics
Cancer Res., June 15, 2004; 64(12): 4112 - 4116.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. L. Fenton, A. Dallol, A. Agathanggelou, L. Hesson, J. Ahmed-Choudhury, S. Baksh, C. Sardet, R. Dammann, J. D. Minna, J. Downward, et al.
Identification of the E1A-Regulated Transcription Factor p120E4F as an Interacting Partner of the RASSF1A Candidate Tumor Suppressor Gene
Cancer Res., January 1, 2004; 64(1): 102 - 107.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.